Logo
Search
Subscribe
Sign In
Subscribe
Home
Archive
Authors
Monthly Dose
Videocasts
Podcasts
April 2026 | De-Risking What Matters

April 2026 | De-Risking What Matters

Drug development improves when benefit and harm are quantified earlier, new data are generated for a defined purpose, and every tool is tied to a real decision.

Apr 30, 2026

•

4 min read

In vitro

+2

Your Pipeline Dies in the Overlap

Your Pipeline Dies in the Overlap

A practical way to fund only the data that changes decisions, using three curves and one rule: reduce overlap or stop spending

Apr 8, 2026

•

5 min read

Drug Development

+2

Patients First. Platforms Second.

September 2025 Issue

Patients First. Platforms Second.

Ruminations & Ramblings is a new series on the future of drug development—where scientists, executives, and investors meet at the messy middle to ask harder questions and chase fewer myths.

Aug 29, 2025

•

6 min read

90% of clinical drug development still fails – will AI help to de-risk trials?   Do we have the right data to enable it to do so?

90% of clinical drug development still fails – will AI help to de-risk trials? Do we have the right data to enable it to do so?

Yes AI can reduce costs and accelerate timelines, but can it help us make better decisions?

Apr 8, 2026

•

5 min read

AI

+1

“Drug Development is a Math Problem”

“Drug Development is a Math Problem”

Strategies for better predictions

Apr 8, 2026

•

7 min read

AI

+4

Most Popular

Latest Posts

April 2026 | De-Risking What Matters

Drug development improves when benefit and harm are quantified earlier, new data are generated for a defined purpose, and every tool is tied to a real decision.

Apr 30, 2026

•

4 min read

Szczepan Baran
Brian Berridge
Nick Kelley
Szczepan Baran, +2
April 2026 | De-Risking What Matters

Your Pipeline Dies in the Overlap

A practical way to fund only the data that changes decisions, using three curves and one rule: reduce overlap or stop spending

Apr 8, 2026

•

5 min read

Szczepan Baran
Szczepan Baran
Your Pipeline Dies in the Overlap

90% of clinical drug development still fails – will AI help to de-risk trials? Do we have the right data to enable it to do so?

Yes AI can reduce costs and accelerate timelines, but can it help us make better decisions?

Apr 8, 2026

•

5 min read

Nick Kelley
Nick Kelley
90% of clinical drug development still fails – will AI help to de-risk trials?   Do we have the right data to enable it to do so?

“Drug Development is a Math Problem”

Strategies for better predictions

Apr 8, 2026

•

7 min read

Brian Berridge
Brian Berridge
“Drug Development is a Math Problem”

January 2026 | Subtractive Trust

The advantage is shifting from adding more steps to proving what can be removed by measuring predictivity and using AI inside clear guardrails.

Jan 30, 2026

•

7 min read

Szczepan Baran
Brian Berridge
Nick Kelley
Szczepan Baran, +2
January 2026 | Subtractive Trust

Subscribe to our newsletter


Connect with us


Innovation to Impact;
Ruminations & Ramblings

From idea to impact: candid reflections and sharp provocations on the real journey of innovation in drug development.